View Item 

Show simple item record

Occult hepatitis B virus infection: diagnosis, implications and management?
dc.contributor.authorLok, Anna Suk-Fongen_US
dc.date.accessioned2010-06-01T22:20:04Z
dc.date.available2010-06-01T22:20:04Z
dc.date.issued2004-12en_US
dc.identifier.citationLOK, ANNA SF (2004). "Occult hepatitis B virus infection: diagnosis, implications and management?." Journal of Gastroenterology and Hepatology 19(s7): S114-S117. <http://hdl.handle.net/2027.42/75344>en_US
dc.identifier.issn0815-9319en_US
dc.identifier.issn1440-1746en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/75344
dc.description.abstractOccult hepatitis B virus (HBV) infection is generally defined as the detection of HBV-DNA in the serum or liver tissue of patients who test negative for hepatitis B surface antigen. In most cases, occult HBV infection is related to low level HBV infection with subdetectable levels of HBsAg and not infection with HBV variants that cannot express S proteins or produce S proteins with aberrant epitopes that are not detected by conventional serological assays. Prevalence of occult HBV infection is related to the overall prevalence of HBV infection in that country, being more common in persons with prior exposure to HBV. Occult HBV infection has been found in a substantial proportion of patients with cirrhosis and hepatocellular carcinoma but other causes of liver disease are frequently present. Future studies should focus on delineating the pathogenic role of occult HBV infection and the basis for failure to detect circulating hepatitis B surface antigen.en_US
dc.format.extent50329 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Science Ptyen_US
dc.rights2004 Blackwell Publishing Asia Pty Ltden_US
dc.subject.otherHepatitis B Core Antibodyen_US
dc.subject.otherHepatitis B Surface Antigenen_US
dc.subject.otherHepatitis B Virus DNAen_US
dc.titleOccult hepatitis B virus infection: diagnosis, implications and management?en_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationum* University of Michigan, Ann Arbor, MI, USAen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/75344/1/j.1440-1746.2004.03657.x.pdf
dc.identifier.doi10.1111/j.1440-1746.2004.03657.xen_US
dc.identifier.sourceJournal of Gastroenterology and Hepatologyen_US
dc.identifier.citedreferenceConjeevaram HS, Lok AS. Occult hepatitis B virus infection: a hidden menace? Hepatology 2001; 34: 204 – 6.en_US
dc.identifier.citedreferencePaterlini P, Poussin K, Kew M, Franco D, Brechot C. Selective accumulation of the X transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma. Hepatology 1995; 21: 313 – 231.en_US
dc.identifier.citedreferenceCacciola I, Pollicino T, Squandrito G et al. Quantification of intrahepatic hepatitis B virus (HBV) DNA in patients with chronic HBV infection. Hepatology 2000; 31: 507 – 12.en_US
dc.identifier.citedreferenceBrechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Brechot P. Persistent Hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely ‘occult’? Hepatology 2001; 34: 194 – 203.en_US
dc.identifier.citedreferenceMatsumoto C, Nishioka K, Oguchi T et al. Detection and quantitation of HBV DNA by semi-nested PCR in donated blood: comparison with HBV serological markers. J. Virol. Meth. 1997; 66: 61 – 9.en_US
dc.identifier.citedreferenceIizuka H, Ohmura K, Ishijima A et al. Correlation between anti-HBc titers and HBV DNA in blood units without detectable HBsAg. Vox Sang. 1992; 63: 107 – 11.en_US
dc.identifier.citedreferenceDouglas DD, Taswell H, Rakela J, Rabe D. Absence of hepatitis B virus DNA detected by polymerase chain reaction in blood donors who are hepatitis B surface antigen negative and antibody to hepatitis B core antigen positive from a United States population with a low prevalence of hepatitis B serologic markers. Transfusion 1993; 33: 212 – 16.en_US
dc.identifier.citedreferenceWeinberger KM, Bauer T, Bohm S, Jilg W. High genetic variability of the group-specific-a-determinant of hepatitis B virus surface antigen and the corresponding fragment of the viral polymerase in chronic virus lacking detectable HBsAg in serum. J. Gen. Virol. 2000; 81: 1165 – 74.en_US
dc.identifier.citedreferenceCacciola I, Pollicino T, Squandrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N. Engl. J. Med. 1999; 341: 22 – 6.en_US
dc.identifier.citedreferenceFukuda R, Ishimura N, Niigaki M et al. Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: clinical and virological significance. J. Med. Virol. 1999; 58: 201 – 7.en_US
dc.identifier.citedreferenceJilg W, Sieger E, Zachoval R, Schatzl H. Individuals with antibodies against hepatitis B core antigen as the only serological marker for hepatitis B infection: high percentage of carriers of hepatitis B and C virus. J. Hepatol. 1995; 23: 14 – 20.en_US
dc.identifier.citedreferenceSheu JC, Huang GT, Shih LN et al. Hepatitis C and B viruses in hepatitis B surface antigen-negative hepatocellular carcinoma. Gastroenterology 1992; 103: 1322 – 7.en_US
dc.identifier.citedreferenceYotsuyanagi H, Shintani Y, Moriya K et al. Virologic analysis of non-B, non-C hepatocellular carcinoma in Japan: frequent involvement of hepatitis B virus. J. Infect. Dis. 2000; 181: 1920 – 8.en_US
dc.identifier.citedreferenceLiang TJ, Baruch Y, Ben-Porath E. Hepatitis B virus infection in patients with idiopathic liver disease. Hepatology 1991; 13: 1044 – 51.en_US
dc.identifier.citedreferenceBrechot C, Jaffredo F, Lagorce D et al. Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: results of a European concerted action. J. Hepatol. 1998; 29: 173 – 83.en_US
dc.identifier.citedreferencePollicino T, Squandrito G, Cerenzia G et al. Hepatitis B virus (HBV) maintains its pro-oncogenic properties in case of occult HBV infection. Gastroenterology 2004; 126: 102 – 10.en_US
dc.identifier.citedreferenceTagger A, Donato F, Ribero ML et al. Case-control study on hepatitis C virus as a risk factor for hepatocellular carcinoma: the role of HCV genotypes and the synergism with hepatitis B virus and alcohol. Brescia HCC study. Int. J. Cancer 1999; 81: 695 – 9.en_US
dc.identifier.citedreferenceSeddigh-Tonekaboni S, Waters JA, Jeffers S et al. Effect of variation in the common ‘a’ determinant on the antigenicity of hepatitis B surface antigen. J. Med. Virol. 2000; 60: 113 – 21.en_US
dc.identifier.citedreferenceChung HT, Lai CL, Lok AS. Pathogenic role of hepatitis B virus in hepatitis B surface antigen-negative decompensated cirrhosis. Hepatology 1995; 22: 25 – 9.en_US
dc.identifier.citedreferenceFong TL, Di Bisceglie AM, Gerber MA, Waggoner JG, Hoofnagle JH. Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B. Hepatology 1993; 18: 1313 – 18.en_US
dc.identifier.citedreferenceLiaw YF, Sheen IS, Chen TJ, Chu CM, Pao CC. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology 1991; 13: 627 – 31.en_US
dc.identifier.citedreferenceHuo TI, Wu JC, Lee PC et al. Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. Hepatology 1998; 28: 231 – 6.en_US
dc.identifier.citedreferenceReherman B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patient's recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat. Med. 1996; 2: 1104 – 8.en_US
dc.identifier.citedreferenceYuki N, Nagaoka T, Yamashiro M et al. Long-term histologic and virologic outcomes of acute self-limited hepatitis B. Hepatology 2003; 37: 1172 – 9.en_US
dc.identifier.citedreferenceBeasley RP. Hepatitis B virus: the major etiology of hepatocellular carcinoma. Cancer 1988; 61: 1942 – 56.en_US
dc.identifier.citedreferenceHoofnagle JH, Seeff LB, Bales ZB, Zimmerman HJ. Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. N. Engl. J. Med. 1978; 298: 1379 – 83.en_US
dc.identifier.citedreferenceWachs ME, Amend WJ, Ascher NL et al. The risk of transmission of hepatitis B from HBsAg (–), HBcAb (+), HBcIgM (–) organ donors. Transplantation 1995; 59: 230 – 4.en_US
dc.identifier.citedreferenceDickson RC, Everhart JE, Lake JR et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology 1997; 113: 1668 – 74.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1440-1746.2004.03657.x.pdf
Size:
49.14KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.